stoxline Quote Chart Rank Option Currency Glossary
  
Apollomics, Inc. (APLM)
7  -0.08 (-1.13%)    02-19 12:40
Open: 7.1
High: 7.35
Volume: 9,621
  
Pre. Close: 7.08
Low: 6.62
Market Cap: 8(M)
Technical analysis
2025-02-19 12:17:24 PM
Short term     
Mid term     
Targets 6-month :  10.57 1-year :  12.49
Resists First :  9.04 Second :  10.69
Pivot price 7.87
Supports First :  6.38 Second :  5.3
MAs MA(5) :  7.01 MA(20) :  8.23
MA(100) :  10.85 MA(250) :  24.85
MACD MACD :  -0.8 Signal :  -0.7
%K %D K(14,3) :  22.3 D(3) :  21.6
RSI RSI(14): 35.6
52-week High :  80.5 Low :  6.38
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ APLM ] has closed above bottom band by 24.7%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.01 - 7.06 7.06 - 7.1
Low: 6.91 - 6.95 6.95 - 6.99
Close: 6.94 - 7.02 7.02 - 7.08
Company Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Headline News

Fri, 20 Dec 2024
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewswire

Tue, 10 Dec 2024
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire

Tue, 10 Dec 2024
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan

Thu, 21 Nov 2024
Apollomics announces 1-for-100 reverse stock split - Investing.com

Thu, 21 Nov 2024
Apollomics Implements 1-for-100 Reverse Stock Split, Adjusts Warrant Prices | APLM Stock News - StockTitan

Thu, 21 Nov 2024
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 655620 (%)
Held by Institutions 40.2 (%)
Shares Short 11 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.31e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 431.6 %
Return on Equity (ttm) -62.8 %
Qtrly Rev. Growth 2.1e+006 %
Gross Profit (p.s.) 267.65
Sales Per Share -152.36
EBITDA (p.s.) 2.14286e+006
Qtrly Earnings Growth -15 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 0.36
Stock Dividends
Dividend 0
Forward Dividend 3710
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android